In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...

Among patients with resected stage 3B to 4 melanoma, postsurgical treatment with Opdivo (nivolumab) was associated with a ...

Introduction Therapeutic exercise has been used to improve cancer-related dysfunction. Recent studies suggest that exercise ...

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

Tagrisso combined with chemotherapy improved overall survival in EGFR-mutated NSCLC patients, including those with poor ...

It has been a busy and largely productive week for small-cap miners, leaving investors slightly more satisfied with their lot ...

Univariate analysis showed that factors such as grade level, family economic status, reasons for choosing nursing major, exposure to AI related courses/training, and daily AI usage time had ...

Watch parts 1 and 2 of our conversation with Dr Collins.

Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.

Playing around with AI is a far cry from implementing it meaningfully in your business. As the technology continues to evolve ...

The HERCULES trial shows pembrolizumab plus chemotherapy produces a 39.4% response rate in advanced penile cancer, offering new treatment hope globally.

“This is a very important addition to our mineral portfolio,” stated Mr. Corrado De Gasperis, Comstock’s Executive Chairman and CEO, “as it could conveniently host activities to support the mining at ...